Drug class
Recombinant activated human coagulation factor VIIa (rFVIIa; bypassing haemostatic agent)
Mechanism of action
Activated factor VII promotes haemostasis by binding tissue factor and activating factor X, increasing thrombin generation and fibrin formation through a pathway that can bypass deficient or inhibited factor VIII or IX.
General use cases
- Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in adults and adolescents aged 12 years or older with congenital haemophilia and inhibitors to factor VIII or IX, or expected poor response to factor replacement, under the Cevenfacta authorisation
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
